Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Illumina (ILMN) to $180 from $184 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech ...
With a Zacks Rank #1 (Strong Buy) at present, the global diagnostics company is gaining more market shares from the strength of the Afirma solution. Veracyte is also making strides with the Decipher ...